drugset / Trial / NCT02900560
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to determine the optimal dose of CC-486 (oral azacitidine) in combination with pembrolizumab for the treatment of platinum-resistant/refractory Epithelial Ovarian Cancer (EOC).
Timeline
- Start
- 2016-12-20
- Primary completion
- 2021-05-27
- Completion
- 2021-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Azacitidine | Other / unclassified | 100 mg | Oral |
| Comparator | Azacitidine | Other / unclassified | 300 mg | Oral |
| Comparator | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |